The Claude maker is targeting a Nasdaq debut under ANT. The bullish case rests on enterprise expansion, better economics for running AI models and a first earnings report that matters more than the opening trade.
November 18, 2026 | Pre-pricing
Anthropic PBC…
An upsized $317.5 million offering gives Lycia Therapeutics (NASDAQ: LYCA) fresh capital to pursue protein-degrading medicines, with early human data and 2027 clinical milestones sharpening the investment story.
October 24, 2026
Wall Street has found a biotechnology company with an unusually literal…
Oura’s proposed Nasdaq debut under OURA is shaping up as more than another wearable-device listing. It is a high-growth health-intelligence story built around a deceptively simple object: a screenless ring that turns sleep, stress, activity, heart health, metabolic health, and women’s health data into…
